Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.

OBJECTIVES The aim of this study was to describe hospital variation and factors associated with adherence to guidelines for implantable cardioverter-defibrillator (ICD) therapy. BACKGROUND Studies have shown incomplete application of ICD therapy in eligible heart failure (HF) patients. METHODS New or discharge prescription rates for ICD therapy (ejection fraction <or=30% without documented ICD contraindications) for hospitals were calculated from participants in the GWTG-HF (Get With The Guidelines-Heart Failure) registry during January 2005 to June 2007. With hierarchical modeling, hospitals' patient case-mix adjusted ICD rate and hospital factors associated with ICD use were determined. The association of ICD rate and other quality of care indicators and procedure use was determined. RESULTS Overall use of ICD in-hospital or planned implantation rate was 20%. This rate ranged widely among hospitals, from 1% among the lowest tertile to 35% among the top tertile (p < 0.01). After adjusting for patient case mix, independent hospital characteristics associated with higher ICD use were percutaneous coronary intervention, coronary artery bypass grafting, and heart transplant capability as well as larger hospital bed size (p < 0.01). Hospital Centers for Medicare and Medicaid Services/Joint Commission on the Accreditation of Healthcare Organizations performance measures (discharge instructions, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, smoking cessation; p >or= 0.05) were similar across ICD, whereas higher ICD-rate hospitals had higher adherence to GWTG-HF performance measures (beta-blocker use, evidence-based beta-blocker use, aldosterone-antagonist, hydralazine/nitrate; p < 0.05) except warfarin in patients with atrial fibrillation (p = 0.18). CONCLUSIONS There is significant unexplained hospital variation in the use of ICD therapy among potentially eligible HF patients. However, hospitals that use ICD therapy more often also have more rapidly adopted other newer evidence-based HF therapies.

[1]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[2]  K. Labresh,et al.  Get with the guidelines. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  P. Austin,et al.  Community factors, hospital characteristics and inter-regional outcome variations following acute myocardial infarction in Canada. , 2005, The Canadian journal of cardiology.

[4]  Robert S. Huckman,et al.  Technological Development and Medical Productivity: The Diffusion of Angioplasty in New York State , 2002, Journal of health economics.

[5]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[6]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[7]  C. Yancy,et al.  Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. , 2007, JAMA.

[8]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[9]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.

[10]  A. Skene,et al.  Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis , 1999, Heart.

[11]  C. Furberg,et al.  From knowledge to practice in chronic cardiovascular disease: a long and winding road. , 2004, Journal of the American College of Cardiology.

[12]  K. Schulman,et al.  Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. , 2007, JAMA.

[13]  R. Gliklich,et al.  Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.

[14]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[15]  V. Ho Certificate of need, volume, and percutaneous transluminal coronary angioplasty outcomes. , 2004, American heart journal.

[16]  R. Gliklich,et al.  Using "get with the guidelines" to improve cardiovascular secondary prevention. , 2003, Joint Commission journal on quality and safety.